PubMed Health⌕ Search

Biomedical subjects

Y Bounameaux

Publications and source records attributed to Y Bounameaux.

At least 19 recordsLinked to original sources
PubMed1988

Acute effects of retinoids on fibrinolysis before and after venous occlusion in healthy humans.

The effects of acitretin and etretinate on the fibrinolytic system have been investigated in a double-blind, placebo-controlled cross-over study in twelve healthy volunteers. Euglobulin fibrinolytic activity, euglobulin clot lysis time, tissue-type plasminogen activator (t-PA) activity and antigen concentration in plasma were measured before and after 10 min of venous occlusion (VO), three hours after ingestion of the compounds. The plasminogen activator inhibitor (PAI) activity was also measured in each session before fibrinolysis stimulation. None of the parameters studied was significantly affected by the two retinoids in comparison with placebo. Our study demonstrates that a single oral dose of 100 mg of etretinate or acitretin, investigated 3 hours after drug administration does not significantly influence the fibrinolytic system in vivo in humans. This observation does not exclude an effect of retinoids after prolonged intake.

Adult↗
PubMed1988

Double-blind study comparing cimetidine and two doses of a slow release formulation of trimoprostil in duodenal ulcer patients with a 6-month follow-up.

120 adult outpatients with endoscopically proven duodenal ulcer were randomly allocated to three groups of 40, treated in a double-blind manner with cimetidine 400 mg twice daily, trimoprostil 3 mg twice daily and trimoprostil 3 mg at bedtime. Trimoprostil was administered as a slow release formulation. Healing rates after 4 weeks were 78, 74 and 58%, respectively, the difference being not significant (p = 0.12). Similarly there was no significant difference regarding subjective symptoms, side effects and biochemical analysis. Healed patients were followed at bimonthly intervals for 6 months. The relapse rates were 71, 59 and 61% for patients initially treated with cimetidine, trimoprostil 6 or 3 mg, respectively, a difference not statistically significant.

Adolescent↗
PubMed1984

[Teratogenic effects of etretinate in humans].

Etretinate (Tigason) is an orally administered retinoid which is used primarily for the treatment of severe keratinization disorders of the skin. The compound has been shown by animal studies to be teratogenic. Because of its lengthy period of storage in the body, the teratogenic risk in humans persisting even after cessation of therapy is an important problem. Despite insistent warnings, female patients have become pregnant in temporal relationship to etretinate therapy. According to observations reported to the manufacturers until February 1984, 19 women had taken etretinate during pregnancy; ten of these patients bore children with no recognizable teratogenic abnormalities. Three women bore children with skeletal defects which had to be attributed to etretinate. One woman had a spontaneous abortion in the 5th month; the fetus was found to have a meningomyelocele. Two fetuses which were aborted for medical reasons had marked cerebral abnormalities. A further 3 fetuses from interrupted pregnancies showed no defects. Among 18 women who became pregnant within two years after etretinate having been discontinued there was no case of teratogenic damage to the embryo. Even if, to date, no malformed infants have been born to woman conceiving after stopping etretinate therapy, the stipulated period of pregnancy prevention after withdrawal of etretinate must continue to be scrupulously respected, since etretinate is apparently teratogenic.

Abnormalities, Drug-Induced↗
PubMed1983

Etretinate in severe psoriasis. Results of double-blind study and maintenance therapy in pustular psoriasis.

A randomized double-blind study was performed in forty patients with severe psoriasis. Etretinate, in contrast to placebo, clearly reduced the psoriatic area and severity index score, and this difference was statistically significant from week 2. The results in psoriasis vulgaris were satisfactory in only three of ten patients; however moderate improvement was noticed in four of ten patients. In pustular psoriasis of von Zumbusch type, the drug produced moderate improvement to complete clearing in all four of the treated patients and was regarded as the first-choice therapy in all of them. In erythrodermic psoriasis satisfactory results were obtained in four of six patients. In three of the five patients with psoriatic arthropathy there was a marked improvement of arthralgia. Laboratory investigations did not show significant abnormalities with the exception of an increase of alanine transaminase (ALT; SGPT) in about 20% of the patients. Ten patients with pustular psoriasis (four of them included in the double-blind trial) on long-term, i.e., maintenance, therapy remained free of lesions up to this writing for 3 years. Triglyceride levels were not elevated.

Clinical Trials as Topic↗
PubMed1978

The determination of antithrombin III. Comparison of six methods. Effect of oral contraceptive therapy.

At III levels measured with six methods in 36 people: 10 healthy controls, 10 women taking a progestagen Lynestrenol and 16 women taking a combined oestrogen-progestagen contraceptive pill. The reproducibility and the sensitivity of these methods as well as the correlation between methods were studied. The Hensen and Loeliger technique had a poor reproducibility and the results obtained with the Howie technique were not in good correlation with those obtained with other methods, especially in the group taking oral contraceptives. The two amidolytic methods using chromogenic substrates were found to be very accurate for antithrombin III activity determination. The rocket immunoelectrophoresis was more accurate and more practical than the radial immunodiffusion. With all methods--except the one of Howie--the 10 women taking progestagen Lynestrenol and the 16 taking combined oestrogen-progestagen had a low AT III and differed significantly from the 10 normals tested. No difference was observed between women taking progestagen only or an oestrogen-progestagen combination.

Antithrombin III↗